479 related articles for article (PubMed ID: 33907949)
21. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
22. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY
J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
24. Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis.
Park J; Jung KS; Lee HW; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
Gut Liver; 2017 Nov; 11(6):828-834. PubMed ID: 28651305
[TBL] [Abstract][Full Text] [Related]
25. Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B.
Cho YY; Chang Y; Nam JY; Cho H; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
Gut Liver; 2020 Mar; 14(2):225-231. PubMed ID: 31060115
[TBL] [Abstract][Full Text] [Related]
26. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients.
Tsai HJ; Chuang YW; Lee SW; Wu CY; Yeh HZ; Lee TY
Aliment Pharmacol Ther; 2018 Jun; 47(12):1673-1681. PubMed ID: 29696665
[TBL] [Abstract][Full Text] [Related]
27. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers.
Shaheen AA; AlMattooq M; Yazdanfar S; Burak KW; Swain MG; Congly SE; Borman MA; Lee SS; Myers RP; Coffin CS
Aliment Pharmacol Ther; 2017 Sep; 46(6):599-604. PubMed ID: 28707319
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.
Kuo MT; Hu TH; Hung CH; Wang JH; Lu SN; Tsai KL; Chen CH
Aliment Pharmacol Ther; 2019 Jan; 49(2):218-228. PubMed ID: 30484881
[TBL] [Abstract][Full Text] [Related]
29. Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment.
Wong GL; Chan HL; Tse YK; Yip TC; Lam KL; Lui GC; Szeto CC; Wong VW
Aliment Pharmacol Ther; 2018 Nov; 48(9):984-992. PubMed ID: 30125952
[TBL] [Abstract][Full Text] [Related]
30. Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients.
Lee J; Park JY; Yang SJ; Lee JY; Kim DG; Joo DJ; Kim MS; Kim SI; Lee JG
J Viral Hepat; 2020 Aug; 27(8):818-825. PubMed ID: 32302037
[TBL] [Abstract][Full Text] [Related]
31. Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B.
Jung CY; Kim HW; Ahn SH; Kim SU; Kim BS
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):956-958.e2. PubMed ID: 34029751
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone.
Lin S; Fu Y; Wu W; Chen T; Chen N; Xun Z; Liu C; Ou Q; Zeng Y; Huang H
Int J Med Sci; 2020; 17(10):1458-1463. PubMed ID: 32624702
[No Abstract] [Full Text] [Related]
33. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients.
Park JW; Kwak KM; Kim SE; Jang MK; Suk KT; Kim DJ; Park SH; Lee MS; Kim HS; Park CK
BMC Gastroenterol; 2017 Mar; 17(1):39. PubMed ID: 28279168
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
[TBL] [Abstract][Full Text] [Related]
35. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
[TBL] [Abstract][Full Text] [Related]
36. Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant.
Lai MC; Lian JS; Zhang WJ; Xu J; Zhou L; Zheng SS
Math Biosci Eng; 2019 Oct; 17(1):627-635. PubMed ID: 31731368
[No Abstract] [Full Text] [Related]
37. Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation.
Hung CH; Hu TH; Lu SN; Lee CM; Chen CH; Kee KM; Wang JH; Tsai MC; Kuo YH; Chang KC; Chiu YC; Chen CH
Antimicrob Agents Chemother; 2015; 59(6):3168-73. PubMed ID: 25779569
[TBL] [Abstract][Full Text] [Related]
38. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study.
Batirel A; Guclu E; Arslan F; Kocak F; Karabay O; Ozer S; Turanli M; Mert A
Int J Infect Dis; 2014 Nov; 28():153-9. PubMed ID: 25286184
[TBL] [Abstract][Full Text] [Related]
39. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial.
Yim HJ; Kim IH; Suh SJ; Jung YK; Kim JH; Seo YS; Yeon JE; Kim CW; Kwon SY; Park SH; Lee MS; Um SH; Byun KS
J Viral Hepat; 2018 Nov; 25(11):1321-1330. PubMed ID: 29772084
[TBL] [Abstract][Full Text] [Related]
40. Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study.
Lee J; Lee JG; Hwang S; Lee KW; Kim JM; Ryu JH; Kim BW; Choi DL; You YK; Kim DS; Nah YW; Kang KJ; Cho JY; Yu HC; Hong G; Choi D; Moon JI; Kim MS
Hepatol Int; 2022 Jun; 16(3):537-544. PubMed ID: 35467324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
